A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca LP
Start Date
April 11, 2019
End Date
January 15, 2021
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca LP
Start Date
April 11, 2019
End Date
January 15, 2021